Benutzer: Gast  Login
Dokumenttyp:
journal article 
Autor(en):
Muller, T; Glass, J; Muller, D; Link, A; Schenk, C; Rammes, G 
Titel:
A new galenic formulation of selegiline (Xilopae) in the treatment of Parkinson disease 
Abstract:
Selegiline is a selective and irreversible inhibitor of monoamine oxidase B (MAO-B). Selegiline is looked upon as a putative progression of Parkinson's disease (PD) delaying compound due to its in preclinical research proven neuroprotective modes of action. Xilopar(R) is a new formulation of selegiline, which facilitates absorption in the mouth and thus avoids hepatic first-pass metabolism. Intake of 1.25 mg Xilopar(R) provides similar pharmacokinetic plasma behaviour corresponding to oral admin...    »
 
Zeitschriftentitel:
AKTUEL NEUROL 
Jahr:
2004 
Band / Volume:
31 
Heft / Issue:
Seitenangaben Beitrag:
347-352 
Sprache:
eng 
Print-ISSN:
0302-4350 
TUM Einrichtung:
sthesiologie